DURHAM – Durham drugmaker Novan has agreements in place to sell its assets as the company’s bankruptcy moves forward.
Novan reached an agreement with Australian company Mayne Pharma for assets related to Rhofade, a commercial product that Novan added through its acquisition last year of EPI Health.
Mayne Pharma will pay $8 million in cash for the assets.